Don't expect an oversold bounce here.
The charts make ZYNE look bearish and not particularly attractive, so avoid.
GH investors could risk a trade under $83 while probing the long side with price targets of $105 and $112.
INTC might surprise on the upside, but charts show prices likely to rally toward $54, then stall.
Here's how to play this biotech stock.
The social media company's stock already has tripled in value since late last year, and a modest correction could be at hand before its shares renew gains.
Owners of Apple could be treated to a positive earnings report next week.
Let's check the charts and indicators because I am pretty sure Warren Buffett is not a chart reader.
Let's check out the latest HD charts.
After nearly going belly up a decade ago, ETFC's combination of higher profits and a much lower stock price makes it look very attractive.
The S&P 500 was up 8, and breadth was negative; meanwhile, Nasdaq saw new lows expand to 115, while essentially up all day -- there's no good way to spin that.
Beverage company could bubble over to the $61 area.
UTX's indicators look mixed and Tuesday's earnings could tip the scales.
Prices are about about 50% from their late December nadir.
Here is my technical strategy approach on ROP.
The drone maker already has had a great run this year and its technical signs indicate the move upward could continue.
Only two indices remain in near-term uptrends.
Traders should be aware that the marketplace is a discounting mechanism and approach Disney shares accordingly.
Let's call in a delivery of some charts and indicators.
Here are some tools to determine whether we can expect big market shifts.
Charles Schwab appears headed into another record year, yet the stock had fallen to just over $40 -- that pullback smells like opportunity.
We're in for more volatility, but complacency is getting wrung out -- plus, what about those banks?
For small investors and traders without the resources of major funds, the price action is a cheap road map.
We cannot rule out new lows for a move down in the weeks ahead.
Let's review the charts and indicators to round out the analysis.
Both names receive quant upgrades and have strong charts.
NVS been in an uptrend the past twelve months.
The action in JD is setting up very well going into the fall.
Let's check the latest charts and indicators on NUE.
I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource.